- Home
- STRO vs REFI Comparison
STRO vs REFI Comparison
Compare STRO & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- REFI
- Stock Information
- Founded
- STRO 2003
- REFI 2021
- Country
- STRO United States
- REFI United States
- Employees
- STRO N/A
- REFI N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- REFI Real Estate Investment Trusts
- Sector
- STRO Health Care
- REFI Real Estate
- Exchange
- STRO Nasdaq
- REFI Nasdaq
- Market Cap
- STRO 292.6M
- REFI 306.1M
- IPO Year
- STRO 2018
- REFI 2021
- Fundamental
- Price
- STRO $2.76
- REFI $16.08
- Analyst Decision
- STRO Strong Buy
- REFI Buy
- Analyst Count
- STRO 7
- REFI 2
- Target Price
- STRO $12.14
- REFI $20.00
- AVG Volume (30 Days)
- STRO 863.7K
- REFI 77.1K
- Earning Date
- STRO 11-13-2024
- REFI 11-07-2024
- Dividend Yield
- STRO N/A
- REFI 11.70%
- EPS Growth
- STRO N/A
- REFI N/A
- EPS
- STRO N/A
- REFI 2.00
- Revenue
- STRO $160,955,000.00
- REFI $56,860,278.00
- Revenue This Year
- STRO N/A
- REFI N/A
- Revenue Next Year
- STRO N/A
- REFI $4.27
- P/E Ratio
- STRO N/A
- REFI $8.04
- Revenue Growth
- STRO 230.90
- REFI 6.49
- 52 Week Low
- STRO $2.45
- REFI $14.82
- 52 Week High
- STRO $6.13
- REFI $17.65
- Technical
- Relative Strength Index (RSI)
- STRO 37.80
- REFI 62.28
- Support Level
- STRO $2.55
- REFI $15.96
- Resistance Level
- STRO $2.76
- REFI $16.18
- Average True Range (ATR)
- STRO 0.26
- REFI 0.15
- MACD
- STRO -0.03
- REFI 0.03
- Stochastic Oscillator
- STRO 17.22
- REFI 80.26
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.